Pimozide is one of the more specialised antipsychotics in modern practice. Its FDA-approved indication is for motor and phonic tics in Tourette syndrome that have not responded to standard treatment. But within psychiatry, pimozide has a long and somewhat controversial reputation as a drug particularly used for delusional disorder — a condition where the central problem is one or more fixed false beliefs, often without the broader features of schizophrenia. Whether the evidence supports that reputation is a more complicated story.
Pimozide is a high-potency antipsychotic FDA-approved for Tourette syndrome, used off-label in delusional disorder, and demanding careful attention to QT interval and drug interactions.
What pimozide is
Pimozide is a diphenylbutylpiperidine — a small chemical class of its own — and was first developed in the 1960s. It binds tightly to dopamine D2 receptors with relatively long duration of action. It has minimal histamine, anticholinergic, or alpha-adrenergic activity, which contributes to a comparatively focused side effect profile.
The Tourette indication
Pimozide is FDA-approved for the suppression of motor and phonic tics in patients with Tourette syndrome whose tics have not responded to standard treatments and who are causing significant impairment. It is generally reserved for selected cases because of cardiac monitoring requirements and side effect profile. The FDA label details the approved use.
The delusional disorder reputation
The idea that pimozide is uniquely effective for delusional disorder dates back to small open-label studies and case series from the 1970s and 1980s. Those reports were striking — particularly in monodelusional disorders such as delusional parasitosis (the fixed belief that one is infested with parasites) — but they were not large randomised trials. Subsequent reviews, including in the Cochrane Library, have concluded that the evidence for pimozide's superiority over other antipsychotics in delusional disorder is limited and that other antipsychotics likely work equally well.
Despite that, pimozide remains a recognised option in delusional disorder — partly because it is well-known to clinicians who treat the condition, partly because some patients have responded to it, and partly because the older case-series tradition has not been formally overturned. It is an off-label use; modern practice often considers second-generation alternatives as well.
How it is dosed
Pimozide is started at low doses (often 0.5–1 mg/day for Tourette syndrome) and titrated cautiously, with ECG monitoring at baseline and during dose increases. Doses for delusional disorder, where used, are typically in a similar low range. The slow titration reflects both the cardiac risk and the long half-life — pimozide takes time to reach steady state.
Side effects
EPS
As a high-potency D2 blocker, pimozide can produce parkinsonism, akathisia, dystonia, and over time tardive dyskinesia. See our EPS overview and our TD article.
Cardiovascular
Pimozide is among the antipsychotics most associated with QTc prolongation. ECG monitoring is required at baseline, after dose changes, and periodically thereafter. Pimozide is contraindicated with other QT-prolonging drugs, in the setting of significant electrolyte abnormalities, and in patients with congenital long QT syndrome. See our QT prolongation article.
Pimozide should not be prescribed without baseline ECG, attention to potassium and magnesium levels, and a careful review of all other medications for QT-prolonging interactions.
Drug interactions (CYP3A4 and CYP2D6)
Pimozide is metabolised by CYP3A4 and CYP2D6. Inhibitors of these enzymes — including many antibiotics (clarithromycin, erythromycin), antifungals (ketoconazole, itraconazole), some antidepressants, and grapefruit juice — can raise pimozide levels and dangerously increase QT risk. The FDA label lists explicit contraindications.
Hyperprolactinemia, sedation, weight
Prolactin elevation occurs as with other D2 blockers. Sedation is typically mild. Weight gain is usually modest.
Neuroleptic malignant syndrome
Rare but possible. See our NMS article.
Where pimozide fits
- Tourette syndrome with tics that have not responded to first-line treatments and are causing significant impairment
- Delusional disorder, particularly monodelusional presentations such as delusional parasitosis, when other agents have not worked or when prescriber expertise lies with pimozide — though second-generation antipsychotics are often considered first today
Where it doesn't fit
- Patients with cardiac conduction abnormalities, congenital long QT, or unstable electrolytes
- Patients on multiple QT-prolonging medications
- Patients on strong CYP3A4 or CYP2D6 inhibitors
- Patients with prior severe EPS
Questions to ask
- Why pimozide rather than another antipsychotic?
- How will we monitor my heart (ECG schedule) and electrolytes?
- What other medications and even foods should I avoid while on it?
- What dose are we aiming for, and over what timeline?
The big picture
Pimozide is a serious, narrowly used drug. For Tourette syndrome and selected cases of delusional disorder, it has a real role — particularly in the hands of clinicians experienced with it. For most patients with schizophrenia, other antipsychotics are usually preferred. The cardiac monitoring requirement is real and not negotiable, and the drug interaction list deserves careful attention. As always, whether pimozide fits is a discussion to have with your prescriber, weighing the specifics of your condition, your other medications, and your medical history.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.